Most studies attempting to induce oral tolerance by producing an anti-inflammatory response to decrease inflammation in autoimmune disease have intravenously administered the same antigen that originally induced the pathology [for instance, oligodendrocyte myelin glycoprotein in experimental encephalomyelitis and type I diabetes] (44, 45). The gene discussed is OMG; the disease is autoimmune disease.